Amgen Wants Biosimilar Halted For Full Fed. Circ. Review
Amgen Inc. implored the Federal Circuit on Wednesday to halt the impending release of Sandoz Inc.'s biosimilar Zarxio until a call is made on Amgen's bid for en banc reconsideration of...To view the full article, register now.
Already a subscriber? Click here to view full article